Neutralizing antibodies against the SARS-CoV-2 Delta and Omicron variants following heterologous CoronaVac plus BNT162b2 booster vaccination

Pérez-Then, Eddy; Lucas, Carolina; Monteiro, Valter Silva; Miric, Marija; Brache, Vivian; Cochón, Leila; Vogels, Chantal B.F.; Malik, Amyn A.; Cruz, Elena De la; Jorge, Aidelis; Santos, Margarita De los; León, Patricia de; Breban, Mallery I.; Billig, Kendall; Yıldırım, İnci; Pearson, Claire; Downing, Randy; Gagnon, Emily; Muyombwe, Anthony; Razeq, Jafar; Campbell, Melissa; Ko, Albert I.; Omer, Saad B.; Grubaugh, Nathan D.; Vermund, Sten H.; Iwasaki, Akiko

doi:10.1038/s41591-022-01705-6

Cited by 364 publications

(360 citation statements)

References 21 publications

Supporting

Mentioning

314

Contrasting

Order By: Relevance

“…Moreover, a heterologous booster dose can enhance more potent protection and neutralizing antibodies compared with a homologous booster dose [265]. This agrees with the results of Pérez-Then E, et al, who found that having a heterologous booster dose of BNT162b2 (Pfizer-BioNTech COVID-19 vaccine) for participants who had primary two doses of Sinovac vaccine, can cause increased neutralizing antibodies against Delta variant to be similar to those who received two doses of BNT162b2 vaccines and can increase the antibodies by 1.4-fold against Omicron variant compared to two doses of BNT162b2 vaccines [266].…”

Section: Is the Booster Dose Useful Or Not?supporting

confidence: 91%

SARS-CoV-2 and Coronavirus Disease Mitigation: Treatment Options, Vaccinations and Variants

et al. 2022

View full text Add to dashboard Cite

COVID-19 is caused by a novel coronavirus (2019-nCoV), which was declared as a pandemic after it emerged in China 2019. A vast international effort has been conducted to prevent and treat COVID-19 due to its high transmissibility and severe morbidity and mortality rates, particularly in individuals with chronic co-morbidities. In addition, polymorphic variants increased the need for proper vaccination to overcome the infectivity of new variants that are emerging across the globe. Many treatment options have been proposed and more than 25 vaccines are in various stages of development; however, the infection peaks are oscillating periodically, which raises a significant question about the effectiveness of the prevention measures and the persistence of this pandemic disease. In this review, we are exploring the most recent knowledge and advances in the treatment and vaccination options as well as the new emerging variants of 2019-nCoV and the possible mitigation of one of the most aggressive pandemics in the last centuries.

show abstract

Section: Is the Booster Dose Useful Or Not?supporting

confidence: 91%

SARS-CoV-2 and Coronavirus Disease Mitigation: Treatment Options, Vaccinations and Variants

et al. 2022

View full text Add to dashboard Cite

show abstract

“…The findings are suggestive of considerable heterogeneity in the magnitude and breadth of neutralization responses of Omicron in different groups ( Sievers et al, 2022 ). After 2 doses of Heterologous vaccination with CoronaVac vaccine there was no detectable Omicron neutralization but when boosted with BNT162b2, it showed 1.4 fold higher neutralization in comparison to 2 doses of mRNA vaccine ( Pérez-Then et al, 2022 ).…”

Section: Booster Shots Of Vaccinesmentioning

confidence: 99%

Emergence of SARS-CoV-2 Omicron (B.1.1.529) variant, salient features, high global health concerns and strategies to counter it amid ongoing COVID-19 pandemic

Khandia

Singhal

Alqahtani

et al. 2022

Environmental Research

247

196

View full text Add to dashboard Cite

Since the appearance in the late of December 2019, SARS-CoV-2 is rapidly evolving and mutating continuously, giving rise to various variants with variable degrees of infectivity and lethality. The virus that initially appeared in China later mutated several times, wreaking havoc and claiming many lives worldwide amid the ongoing COVID-19 pandemic. After Alpha, Beta, Gamma, and Delta variants, the most recently emerged variant of concern (VOC) is the Omicron (B.1.1.529) that has evolved due to the accumulation of high numbers of mutations especially in the spike protein, raising concerns for its ability to evade from pre-existing immunity acquired through vaccination or natural infection as well as overpowering antibodies-based therapies. Several theories are on the surface to explain how the Omicron has gathered such a high number of mutations within less time. Few of them are higher mutation rates within a subgroup of population and then its introduction to a larger population, long term persistence and evolution of the virus in immune-compromised patients, and epizootic infection in animals from humans, where under different immune pressures the virus mutated and then got reintroduced to humans. Multifaceted approach including rapid diagnosis, genome analysis of emerging variants, ramping up of vaccination drives and receiving booster doses, efficacy testing of vaccines and immunotherapies against newly emerged variants, updating the available vaccines, designing of multivalent vaccines able to generate hybrid immunity, up-gradation of medical facilities and strict implementation of adequate prevention and control measures need to be given high priority to handle the on-going SARS-CoV-2 pandemic successfully.

show abstract

“…The heterologous boosting strategy refers to administering a vaccine that differs from the previous vaccine platform, potentially improving the immunogenicity and expanding the breadth of cellular and humoral immunity against current SARS-CoV-2 variants of concern (Barros-Martins et al, 2021;Munro et al, 2021). Heterologous boosting of CoronaVac with mRNA vaccine have shown not only induced the greater antibody response compared to other booster vaccine platform but also produced neutralizing antibodies against ancestral, Delta, and Omicron SARS-CoV-2 strain (Cheng et al, 2022;Costa Clemens et al, 2022;Perez-Then et al, 2022). The mRNA-1273 vaccine booster was administered 6 months after the second CoronaVac vaccination.…”

Section: Main Textmentioning

confidence: 99%

Antibody response after a third dose mRNA-1273 vaccine among vaccinated healthcare workers with two doses of inactivated SARS-CoV-2 vaccine

Cucunawangsih

Wijaya

Lugito

et al. 2022

International Journal of Infectious Diseases

View full text Add to dashboard Cite

Neutralizing antibodies against the SARS-CoV-2 Delta and Omicron variants following heterologous CoronaVac plus BNT162b2 booster vaccination

Cited by 364 publications

References 21 publications

SARS-CoV-2 and Coronavirus Disease Mitigation: Treatment Options, Vaccinations and Variants

SARS-CoV-2 and Coronavirus Disease Mitigation: Treatment Options, Vaccinations and Variants

Emergence of SARS-CoV-2 Omicron (B.1.1.529) variant, salient features, high global health concerns and strategies to counter it amid ongoing COVID-19 pandemic

Antibody response after a third dose mRNA-1273 vaccine among vaccinated healthcare workers with two doses of inactivated SARS-CoV-2 vaccine

Contact Info

Product

Resources

About